- Home
- FACT vs BWAY Comparison
FACT vs BWAY Comparison
Compare FACT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FACT
- BWAY
- Stock Information
- Founded
- FACT 2024
- BWAY 2003
- Country
- FACT United States
- BWAY Israel
- Employees
- FACT N/A
- BWAY N/A
- Industry
- FACT
- BWAY Medical/Dental Instruments
- Sector
- FACT
- BWAY Health Care
- Exchange
- FACT NYSE
- BWAY Nasdaq
- Market Cap
- FACT 250.5M
- BWAY 207.4M
- IPO Year
- FACT 2024
- BWAY 2019
- Fundamental
- Price
- FACT $10.07
- BWAY $8.24
- Analyst Decision
- FACT
- BWAY Strong Buy
- Analyst Count
- FACT 0
- BWAY 3
- Target Price
- FACT N/A
- BWAY $13.17
- AVG Volume (30 Days)
- FACT 98.6K
- BWAY 31.1K
- Earning Date
- FACT 01-01-0001
- BWAY 05-07-2025
- Dividend Yield
- FACT N/A
- BWAY N/A
- EPS Growth
- FACT N/A
- BWAY N/A
- EPS
- FACT N/A
- BWAY 0.09
- Revenue
- FACT N/A
- BWAY $41,016,000.00
- Revenue This Year
- FACT N/A
- BWAY $349.63
- Revenue Next Year
- FACT N/A
- BWAY $27.16
- P/E Ratio
- FACT N/A
- BWAY $54.30
- Revenue Growth
- FACT N/A
- BWAY 29.04
- 52 Week Low
- FACT $9.85
- BWAY $4.61
- 52 Week High
- FACT $10.32
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- FACT N/A
- BWAY 32.71
- Support Level
- FACT N/A
- BWAY $8.29
- Resistance Level
- FACT N/A
- BWAY $8.58
- Average True Range (ATR)
- FACT 0.00
- BWAY 0.53
- MACD
- FACT 0.00
- BWAY -0.05
- Stochastic Oscillator
- FACT 0.00
- BWAY 14.81
About FACT FACT II ACQUISITION CORP
FACT II Acquisition Corp is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.